Stockscreener 앱 받기
6.40
0.16%
-0.010
시간 외 거래:
6.30
-0.10
-1.56%
Upstream Bio Inc 주식(UPB)의 최신 뉴스
UPB|Upstream Bio Inc|Price:6.410|Chg%:+0.010 - TradingKey
Upstream Bio Inc (UPB) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Upstream Bio Inc (UPB) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
TradingKey - TradingKey
Upstream Bio, Inc. Revenue Breakdown – NASDAQ:UPB - TradingView
Upstream Bio Inc (UPB) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Enterprise value to revenue forward of Upstream Bio, Inc. – NASDAQ:UPB - TradingView
Why Did UPB Stock Plunge 40% Today? - Stocktwits
ETFs Investing in Upstream Bio, Inc. Stocks - TradingView
Upstream Bio, Inc. (UPB) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
UPB Q1 2026 Earnings: Narrower Loss Beats Estimates Amid Clinical ProgressEarnings Season Preview - DonanımHaber
Upstream Bio Q1 2026 Earnings: Narrower Loss Beats Expectations, Stock Declines in Pre-Revenue Phase - dars.gov.et
Price to earnings forward of Upstream Bio, Inc. – NASDAQ:UPB - TradingView
Price to book forward of Upstream Bio, Inc. – NASDAQ:UPB - TradingView
UPBUpstream Bio Inc Dividends - Finviz
UPB Q1 2026 Earnings: Narrower-Than-Expected Loss Lifts SharesEarnings Miss Alert - DonanımHaber
Here's Why We're Watching Upstream Bio's (NASDAQ:UPB) Cash Burn Situation - Moomoo
Upstream Bio Inc. (UPB) Q1 2026 Earnings: Narrower-than-Expected Loss Drives Modest Stock DeclineDiluted EPS Report - dars.gov.et
Enterprise value to EBIT forward of Upstream Bio, Inc. – NASDAQ:UPB - TradingView
UpStream Bio(UPB) Stock Options Chain | Quotes & News - Moomoo
Upstream Bio Inc. (UPB) Q1 2026 Earnings: Narrower-than-Expected Loss Drives Positive SentimentGross Profit Margin - dars.gov.et
UPB News | UPSTREAM BIO INC (NASDAQ:UPB) - ChartMill
Upstream Bio, Inc. (UPB) reports Q1 loss, beats revenue estimates - MSN
Upstream Bio, Inc. Actuals & Estimates (NASDAQ:UPB) - TradingView
Upstream Bio, Inc. Actuals & Estimates (BOATS:UPB) - TradingView
UPB Forecast — Price Target — Prediction for 2027 - TradingView
Is Upstream Bio, Inc. (UPB) a Rising Biotech Opportunity After New Analyst Coverage? - Insider Monkey
Enterprise value to EBITDA forward of Upstream Bio, Inc. – NASDAQ:UPB - TradingView
JPMorgan Cuts Upstream Bio Stock Target to Eight Dollars - sekbernews.id
Is Upstream Bio, Inc. (UPB) the Best Low Priced Stocks to Get Rich in 2026? - Yahoo Finance
Upstream Bio (UPB) Consolidates Near Support After Marginal Gains Amid Biotech Sector CautionIV Rank - dars.gov.et
Upstream Bio Inc (UPB) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
UPB Technical Analysis & Stock Price Forecast - Intellectia AI
Upstream Bio Inc (UPB) Valuation: PE, PB & Fair Value Analysis - TradingKey
Upstream Bio Inc (UPB) Institutional Confidence - TradingKey
Top Executive Makes Strategic Move With Upstream Bio Stock - TipRanks
Upstream Bio Inc (UPB) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Upstream Bio Inc (UPB) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Upstream Bio Inc (UPB) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Upstream Bio presents positive Phase 2 trial data for verekitug By Investing.com - Investing.com Nigeria
Upstream Bio presents positive Phase 2 trial data for verekitug - Investing.com
Upstream Bio, Inc. unveils Phase 2 VIBRANT trial data showing majority of verekitug recipients achieve key improvements - Traders Union
Upstream Bio Reports Positive Phase 2 Results for Verekitug in Chronic Rhinosinusitis with Nasal Polyps, Achieving Clinically Meaningful Improvements in Key Symptoms - Quiver Quantitative
Upstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements ... - Caledonian Record
Upstream Bio Presents New Responder Analyses Demonstrating - GlobeNewswire
Upstream Bio Inc. (UPB) Falls 4.39% as Shares Test Key Support LevelGamma Exposure - newsline.com
UPB Q1 2026 Earnings: Narrower-than-Expected Loss as Clinical Progress ContinuesEstimate Accuracy - newsline.com
1.97%
0.83%
자본화:
|
볼륨(24시간):